The Investor
03 Nov 2026, 15:02
BioNTech Edges Up 0.5% as Revenue Guidance Rises and Oncology Pipeline Advances
BioNTech (NASDAQ: BNTX) shares rose about 0.5% after the company reported a return to quarterly profitability, raised the midpoint of its 2026 revenue guidance and highlighted further progress across its oncology pipeline.
Third-quarter revenue was €1.29 billion, down from €1.52 billion a year earlier as expected lower demand for COVID-19 vaccines continued to weigh on sales. However, BioNTech reported net profit of €184.5 million, or €0.73 per diluted share, compared with a €28.7 million loss a year earlier.
Adjusted net profit was €440.9 million, although this was below €752.5 million in the prior-year quarter. Adjusted diluted EPS declined to €1.76 from €3.11. R&D spending increased as BioNTech continued investing in late-stage immuno-oncology and antibody-drug conjugate programs.
The company raised its full-year revenue guidance to €1.7 billion-€1.9 billion from €1.6 billion-€1.9 billion, lifting the midpoint while leaving its adjusted R&D and SG&A spending forecasts unchanged.
Pipeline progress remained central to the investment case. BioNTech reported encouraging data for pumitamig combinations in lung cancer, advanced a Phase 3 trial involving pumitamig and Gilead’s sacituzumab govitecan in triple-negative breast cancer, and said gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer.
BioNTech also maintained a substantial financial cushion, ending September with €16.2 billion in cash, cash equivalents and security investments. The company has additionally repurchased about $463 million of shares under its $1 billion buyback program.
The modest 0.5% gain appears to reflect a balance between improving guidance and oncology progress on one side and declining COVID-related revenue and higher development spending on the other. With a large cash position and several late-stage oncology programs advancing, investor attention is increasingly shifting from the declining vaccine business toward BioNTech’s ability to build a diversified cancer portfolio.
BioNTech (NASDAQ: BNTX) shares rose about 0.5% after the company reported a return to quarterly profitability, raised the midpoint of its 2026 revenue guidance and highlighted further progress across its oncology pipeline.
Third-quarter revenue was €1.29 billion, down from €1.52 billion a year earlier as expected lower demand for COVID-19 vaccines continued to weigh on sales. However, BioNTech reported net profit of €184.5 million, or €0.73 per diluted share, compared with a €28.7 million loss a year earlier.
Adjusted net profit was €440.9 million, although this was below €752.5 million in the prior-year quarter. Adjusted diluted EPS declined to €1.76 from €3.11. R&D spending increased as BioNTech continued investing in late-stage immuno-oncology and antibody-drug conjugate programs.
The company raised its full-year revenue guidance to €1.7 billion-€1.9 billion from €1.6 billion-€1.9 billion, lifting the midpoint while leaving its adjusted R&D and SG&A spending forecasts unchanged.
Pipeline progress remained central to the investment case. BioNTech reported encouraging data for pumitamig combinations in lung cancer, advanced a Phase 3 trial involving pumitamig and Gilead’s sacituzumab govitecan in triple-negative breast cancer, and said gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer.
BioNTech also maintained a substantial financial cushion, ending September with €16.2 billion in cash, cash equivalents and security investments. The company has additionally repurchased about $463 million of shares under its $1 billion buyback program.
The modest 0.5% gain appears to reflect a balance between improving guidance and oncology progress on one side and declining COVID-related revenue and higher development spending on the other. With a large cash position and several late-stage oncology programs advancing, investor attention is increasingly shifting from the declining vaccine business toward BioNTech’s ability to build a diversified cancer portfolio.
